Contribute Try STAT+ Today

As more emphasis is placed on the value of prescription medicines, a new study found cost-effectiveness analyses were unavailable for many of the medicines that accounted for a large share of Medicare Part D spending in 2016. And more than half of the analyses that were conducted failed to meet minimum standards.

Specifically, cost-effectiveness was not studied for 115 of the 250 drugs for which Part D spending was greatest in 2016, the last year for which complete data was available when the study began. Those medicines accounted for 33% of the $146.1 billion in total Part D spending that year, according to the study published in JAMA Network Open.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment